Overview Financials News + Filings Key Docs Charts Ownership Insiders
|
|
NORTHWEST BIOTHERAPEUTICS INC (NWBO)
|
Add to portfolio |
|
|
|
| Price: |
$0.84
| | Metrics |
| OS: |
1.12
|
B
| |
|
|
| Market cap: |
$942
|
M
| |
|
|
|
Net debt:
|
$24.6
|
M
| |
|
|
|
EV:
|
$966
|
M
| | | |
| | | | | |
| TTM Valuation | | | |
|
EBITDA
|
($59.0)
|
M
| |
|
|
|
EBIT
|
($60.3)
|
M
| |
|
|
| EPS |
($0.08)
| |
|
|
|
|
| |
|
|
|
Recent News + Filings (All items)
|
Revenue Mix by Segment
|
Financial Summary (All financials)
| In millions, except per share items | Dec-31-22 | Dec-31-21 | Dec-31-20 | Dec-31-19 | Dec-31-18 | Dec-31-17 | Dec-31-16 | Dec-31-15 |
| Revenues | 1.7 | 1.0 | 1.3 | 2.4 | 0.4 | 0.3 | 0.6 | 1.7 |
| Revenue growth | 67.5% | -22.2% | -46.4% | 485.0% | 22.6% | -46.1% | -64.2% | 19.6% |
| Cost of goods sold | 0.0 | 0.0 | 0.0 | 0.0 | 45.2 | 0.0 | 0.0 | 0.0 |
| Gross profit | 1.7 | 1.0 | 1.3 | 2.4 | -44.8 | 0.3 | 0.6 | 1.7 |
| Gross margin | 100.0% | 100.0% | 100.0% | 100.0% | -10863.3% | 100.0% | 100.0% | 100.0% |
| Research and development | 35.5 | 20.3 | 33.6 | 14.1 | 18.2 | 33.5 | 60.1 | 103.1 |
| General and administrative | 33.4 | 33.4 | 54.3 | 16.3 | 22.5 | 12.5 | 10.9 | 18.3 |
| EBIT | -67.2 | -52.7 | -86.6 | -28.0 | -33.7 | -45.6 | -70.3 | -119.7 |
| EBIT margin | -3991.7% | -5244.0% | -6708.4% | -1161.0% | -8179.9% | -13582.4% | -11288.1% | -6883.7% |
| Pre-tax income | -105.0 | 179.1 | -529.8 | -20.8 | -35.8 | -73.1 | -80.2 | -114.7 |
| Income taxes | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Tax rate | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Net income | -105.0 | 179.1 | -529.8 | -20.8 | -53.6 | -74.4 | -85.9 | -114.7 |
| Net margin | -6238.9% | 17823.5% | -41039.6% | -863.6% | -12999.8% | -22145.5% | -13781.9% | -6598.1% |
| |
| Diluted EPS | ($0.10) | $0.18 | ($0.73) | ($36.89) | ($0.12) | ($0.31) | ($0.77) | ($1.48) |
| Shares outstanding (diluted) | 1,015.9 | 1,007.9 | 725.1 | 0.6 | 440.0 | 242.8 | 111.1 | 77.7 |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|
|